Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
130
NCT05667129
A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 1, 2022
Completion: May 30, 2023
NCT06417697
A Phase 1b Study to Evaluate the Safety of XEN-101
Start: May 24, 2024
Completion: Sep 9, 2024